Natera, Inc. ($NTRA) Stock Forecast: Up 5.1% Today

What is Natera, Inc.?

Natera (NASDAQ: NTRA) operates as a distinguished biotechnology firm specializing in genetic testing and analysis. The company is recognized for its noteworthy growth and advancements in the healthcare domain.

Why is Natera, Inc. going up?

NTRA stock is up 5.1% on Apr 23, 2025 17:23

• Demonstrating a remarkable performance over the last five years, surpassing the market by 19.34% annually, has attracted investors interested in high returns.
• With a focus on genetic testing and a market capitalization of $20.02 billion, Natera holds a prominent position within the biotech sector, instilling confidence in investors.
• The upward trend in NTRA's stock performance today may be linked to the ongoing positive outlook regarding the company's growth potential and market outperformance.

NTRA Price Chart

NTRA Technical Analysis

NTRA News

Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today - Natera ( NASDAQ:NTRA )

Natera NTRA has outperformed the market over the past 5 years by 19.34% on an annualized basis producing an average annual return of 33.37%. Currently, Natera has a market capitalization of $20.02 billion.

https://www.benzinga.com/insights/news/25/04/44879587/heres-how-much-100-invested-in-natera-5-years-ago-would-be-worth-today

Trending Today

Natera, Inc. Price History

13.10.2024 - NTRA Stock was up 15.7%

• Natera (NTRA) reported a Q3 loss but exceeded revenue estimates, which may have positively influenced investor sentiment.
• The bullish position taken by investors in the options market indicates confidence in Natera's future performance.
• The combination of beating revenue estimates and positive investor sentiment from the options market likely contributed to the strong bullish movement in Natera's stock today.

13.10.2024 - NTRA Stock was up 17.2%

• Natera (NTRA) stock experienced a strong bullish movement following the release of its third-quarter financial results.
• Analysts increased their forecasts for Natera after the company reported a quarterly loss that was lower than expected and topped revenue estimates.
• The options market also indicated a bullish sentiment towards Natera, with significant funds taking a positive position in the company.
• The positive performance of Natera stock could be attributed to the company's strong financial results and optimistic revenue guidance for the future, leading to increased investor confidence and driving the stock price higher.

25.01.2025 - NTRA Stock was down 5.1%

• Natera (NTRA) showed significant bearish movement today.
• Comparison with Gilead Sciences (GILD) in the medical stocks sector may have revealed Natera's underperformance, influencing a negative market sentiment.
• Investors are expressing concerns about Natera's competitive position in the sector, potentially impacting its stock price adversely.
• It is likely that Natera encountered specific challenges or setbacks, prompting investors to sell shares and leading to the bearish movement.

18.11.2024 - NTRA Stock was down 5.3%

• Despite the "Golden Cross" signal indicating a bullish trend, Natera (NTRA) has faced bearish movement recently.
• While surpassing the resistance at the 20-day simple moving average could signal short-term bullish momentum, today's bearish movement suggests other influencing factors.
• Factors such as broader market conditions, company-specific news, or profit-taking activities may be contributing to the downward pressure on Natera's stock price.
• Traders should consider technical signals and external factors when deciding on transactions involving Natera (NTRA) in the current market climate.

30.06.2024 - NTRA Stock was down 5.2%

• The bearish movement in NTRA stock could be attributed to the CFO and the president of clinical diagnostics selling significant amounts of company shares, possibly raising concerns among investors about the company's future performance.
• Despite the positive news about the validation of Natera's Signatera test for Merkel Cell Carcinoma, the focus on insider selling might have overshadowed the positive developments in the company.
• Investors might be cautious about the upcoming earnings report, even though Natera is expected to beat earnings estimates. The uncertainty surrounding the stock could have led to profit-taking and contributed to the bearish movement.
• The market might be reacting to the overall selling pressure from company insiders, leading to a negative sentiment towards Natera's stock despite the promising clinical utility of their products.

06.07.2024 - NTRA Stock was up 5.5%

• Participation in a growth conference likely sparked investor interest and confidence in the company's future prospects.
• A presentation by the leadership team may have highlighted innovative strategies and growth opportunities, leading to increased optimism among investors.
• The availability of a live webcast could have provided further insights into advancements in cell-free DNA testing, potentially attracting more attention from the investment community.

07.07.2024 - NTRA Stock was up 6.3%

• Natera has outperformed the market significantly over the past 5 years, showcasing strong growth prospects and investor confidence.
• The company's participation in the Canaccord Genuity 44th Annual Growth Conference likely generated positive investor sentiment and highlighted Natera's strategic initiatives and future growth prospects.
• The live webcast of the event provided investors with an opportunity to gain insights into Natera's advancements in cell-free DNA testing, potentially driving further interest and investment in the company.

09.07.2024 - NTRA Stock was up 6.8%

• Natera reported a Q2 loss but surpassed revenue estimates, indicating strong performance and potential growth prospects.
• The stock has outperformed the market over the past 5 years, showcasing consistent growth and investor confidence.
• Participation in the Canaccord Genuity 44th Annual Growth Conference suggests Natera's commitment to showcasing its strategies and growth prospects, which might have positively influenced investor sentiment.
• Overall, the combination of positive financial results, long-term market outperformance, and active participation in industry events likely contributed to the bullish movement in Natera's stock today.

20.01.2025 - NTRA Stock was down 5.3%

• Over the past 5 years, Natera has outperformed the market significantly with an average annual return of 36.12%.
• Despite breaking above the 20-day moving average recently, suggesting a positive momentum, the stock saw a bearish movement today.
• The bearish movement may be due to profit-taking by investors or broader market factors affecting the stock negatively.
• Investors should monitor any upcoming developments related to Natera to determine if the bearish trend is a temporary correction or a more sustained shift in market sentiment.

11.01.2025 - NTRA Stock was down 3.4%

• Strong performance by Natera in the past 5 years may have prompted profit-taking by investors, resulting in a decline in the stock.
• Investors who had gained significantly from Natera's stock in the past might have opted to divest, contributing to the downward trend in the stock price.
• The market sentiment appears to have turned bearish possibly due to perceived overvaluation following the impressive performance, leading to a sell-off and the observed decline in stock price today.

23.03.2025 - NTRA Stock was up 5.1%

• Demonstrating a remarkable performance over the last five years, surpassing the market by 19.34% annually, has attracted investors interested in high returns.
• With a focus on genetic testing and a market capitalization of $20.02 billion, Natera holds a prominent position within the biotech sector, instilling confidence in investors.
• The upward trend in NTRA's stock performance today may be linked to the ongoing positive outlook regarding the company's growth potential and market outperformance.

28.01.2025 - NTRA Stock was down 5.5%

• The bearish movement in NTRA today could be attributed to the reported Q4 loss, despite topping revenue estimates.
• Investors may have reacted negatively to the earnings surprise and uncertainties about the company's future profitability.
• The market sentiment might have shifted due to concerns raised by the financial performance, leading to a sell-off of Natera shares.
• The slight miss in earnings and revenue could have caused investors to reassess the stock's valuation and potential growth prospects, resulting in the bearish movement observed today.